Blood Cancer Gene Mutation Competition: New QMUL Study Reveals How Mutations Compete Over Time, Offering Clues to Risk

Researchers at Queen Mary University of London's Barts Cancer Institute have made a groundbreaking discovery in understanding blood cancer development. Their latest study, published in the prestigious journal Cancer Discovery, unveils how gene mutations in blood stem cells compete over time, providing vital clues to assessing individual risk for blood cancers like leukaemia.

This work challenges traditional views of mutation accumulation, showing instead a dynamic 'mosaic' of competing cell clones that evolve uniquely in each person as they age. While many accumulate these mutations harmlessly—a phenomenon known as clonal hematopoiesis (CH)—a minority progress to malignancy. The findings could revolutionise risk prediction, enabling earlier interventions and transforming patient outcomes.

🔬 The Science Behind Clonal Hematopoiesis and Blood Cancer Risk

Clonal hematopoiesis refers to the expansion of blood stem cells carrying specific genetic mutations, a common age-related process. By midlife, up to 10-20% of people over 70 may have detectable CH, yet only a fraction develop blood cancers. In the UK, blood cancers affect over 40,000 individuals annually, with leukaemia alone accounting for around 10,000 new cases each year, underscoring the urgency of better risk stratification.

The Queen Mary University study introduces a mathematical model of 'polyclonal competition,' where new fit clones emerge roughly three times per year, vying for dominance in the stem cell pool. Only the strongest persist, with fitter clones appearing later in life via multi-step evolution. Genes like DNMT3A often drive single-hit expansions, while TET2, ASXL1, JAK2, SF3B1, and SRSF2 favour multi-hit paths—insights that pinpoint potential malignancy precursors.

This competitive framework explains why mutation patterns vary individually and intensify with age, creating a crowded stem cell environment. Unlike prior models assuming steady growth of select mutations, this predicts hundreds under selection by age 50, though sequencing limits detection to a few.

Unpacking the Mathematical Model: A Game-Changer from QMUL

At the heart of the research is an innovative agent-based model and stochastic differential equations simulating clone dynamics. Led by Dr. Benjamin Werner, Reader in Somatic Evolution at Barts Cancer Institute, and postdoctoral researcher Dr. Nathaniel Mon Père, the team analysed public sequencing datasets from blood stem cells across lifetimes.

'I was on an aeroplane reading one of these previous studies, and I suddenly realised I could explain the patterns,' recalls Dr. Mon Père. Their model, validated against real data, uses approximate Bayesian computation to infer fitness distributions and clone arrival rates, accurately forecasting genetic diversity shifts from youth to old age.

A signature visualisation, the Muller plot, illustrates this: clones branch left-to-right, acquiring mutations while competing—visual proof of polyclonal rivalry driving CH evolution.

Dr. Werner's expertise in mathematical biology and tumour evolution, honed through prior works on cancer phylogenies, underpins this advance. His group blends computation with genomics to decode somatic evolution, positioning QMUL as a leader in predictive oncology.

Queen Mary University of London's Pivotal Role in Cancer Research

Barts Cancer Institute (BCI), part of Queen Mary University of London (QMUL), stands at the forefront of UK cancer research. Established in 2004, BCI integrates basic science, clinical translation, and computational innovation, with centres like Haemato-Oncology and Cancer Evolution driving blood cancer breakthroughs.

QMUL's strategic location in London's medical hub fosters collaborations with Barts Health NHS Trust, accelerating bench-to-bedside progress. Recent BCI feats include £1m trials for myelodysplastic syndromes and fat-metabolism therapies for acute myeloid leukaemia (AML). This study exemplifies QMUL's commitment to interdisciplinary research, blending maths, genomics, and clinical insight.

For aspiring researchers, QMUL offers vibrant opportunities. Dr. Werner's lab exemplifies how computational roles thrive here, attracting UKRI and Barts Charity funding. UK universities like QMUL lead in this niche, with rising demand for experts in evolutionary dynamics amid genomic data explosion.

Blood Cancers in the UK: Scale, Challenges, and Hope

Blood cancers encompass leukaemia, lymphoma, myeloma, and myelodysplastic syndromes, claiming ~13,000 UK lives yearly. Incidence rises with age, mirroring CH prevalence—~1% at 50, escalating to 20%+ post-70. Despite advances, survival lags solid tumours; e.g., myeloma 5-year rate ~50%.

The QMUL model addresses a core puzzle: why do most CH carriers remain healthy? By distinguishing normal competition from aberrant patterns, it flags early malignancy risks. Clinically, widespread sequencing could identify at-risk individuals for monitoring, akin to BRCA testing in breast cancer.

Read the full study in Cancer Discovery for deeper methodology.

Implications for Early Detection and Precision Medicine

This research heralds a shift from static mutation counts to dynamic evolutionary profiles. Risk tools could predict 'warning signs'—e.g., unusual clone dominance—prompting surveillance or trials. For genes like TET2 (common in CH, linked to myeloid progression), multi-hit patterns signal heightened vigilance.

In the UK, where NHS genomic initiatives like 100,000 Genomes expand, such models integrate seamlessly, potentially averting thousands of cases. Patient advocates praise the focus on prevention, aligning with Blood Cancer UK's push for equitable access.

Challenges persist: sequencing resolution limits detection; ethical issues around over-surveillance loom. Yet, the framework empowers personalised strategies, reducing overtreatment.

Spotlight on the Researchers: Careers in Computational Oncology

Dr. Benjamin Werner, a mathematician-turned-cancer-evolutionist, directs BCI's Evolutionary Dynamics Group. His Google Scholar profile boasts 3700+ citations, spanning ecDNA and phylogenetic modelling. Dr. Nathaniel Mon Père, the idea's spark, exemplifies postdoc pathways at QMUL, blending theory and data.

UK higher education thrives on such talent. Roles in cancer genomics—research assistants to lecturers—abound at QMUL, ICR, CRUK Manchester. Salaries start ~£35k for postdocs, rising to £60k+ for readers, with grants fueling growth.

Broader Impact on UK Higher Education and Research Landscape

QMUL's feat underscores UK unis' prowess in interdisciplinary science. With Cancer Grand Challenges awards and UKRI backing, BCI exemplifies translational hubs. This study bolsters QMUL's rankings in medicine, attracting global talent.

For students, it highlights computational biology's rise—blending maths, AI, genomics. MSc/PhD programs at QMUL equip graduates for booming fields; e.g., bioinformatics roles up 20% amid NHS digitisation.

Stakeholders—from policymakers to charities—eye integration into guidelines. Blood Cancer UK notes ~680 child diagnoses yearly, stressing early-risk tools' value.

Future Directions: From Model to Clinic

Next, Werner's team refines prediction tools, testing against longitudinal cohorts. Collaborations with Sanger Institute (pioneers in CH tracking) promise validation. Trials targeting competitive edges—e.g., TET2 inhibitors—loom.

In UK academia, this fuels hiring: postdocs in evolutionary modelling, PhDs in stem cell genomics. QMUL's ecosystem nurtures careers, from lab techs to PIs.

Optimistically, polyclonal models extend to solid tumours, redefining precision oncology. As Dr. Werner queries: 'Why only a minority develop cancer?'—this edges closer to answers, saving lives.

Photo by National Cancer Institute on Unsplash

Stakeholder Perspectives and Real-World Relevance

• Blood Cancer UK: 'Transformative for risk assessment.'
• NHS Genomics: Aligns with whole-genome sequencing rollout.
• Patients: Empowerment via proactive monitoring.

Economically, averting late-stage diagnoses cuts NHS costs—blood cancers burden billions yearly.